Dow Jones 10478.16 +33.43 1:30 pm PST, April 27, 2004  NASDAQ 2032.53 -4.24 For info, visit access.smallcapnetwork.com S & P 500 1138.15 +2.62 To be removed, please click here Russell 2000 590.75 +1.30 VOLUME 04: ISSUE 31  Feature: Biophan Patents success. Looks like its nanotech week at SmallCap. Yesterday, we Alerted the SmallCap readership to the exciting developments at nanotech-centric Isonics Corp (NASDAQ: ISON). Today, we're updating you on an old friend, bio-medical nanotech concern Biophan (OTCBB: BIPH). Originally Alerted to the readership at 35 cents in December, we advised taking profits a month later at $1.50. While the shares subsequently moved a bit more--to a high of $1.65-- a return of approximately 350 percent was booked in less than 45 days.  At current levels, we continue to suggest strategic accumulation of Biophan shares for both short and especially long-term appreciation. As Biophan shares pulled back in mid-January, we suggested that the $1.00 -$1.20 area looked right to re-establish positions. The stock appears to have built a solid base in that range and today's potent announcement (release below) regarding significant technology patent portfolio growth will likely help the forward progress of the shares. The Biophan corporate mission is quite simple: " to create a world-class biomedical patent portfolio" according to President and CEO Michael Weiner. Today's announcement grows the portfolio to nine patents issued with six more allowed (Allowance means that the patents will now be scheduled for issuance) and more than 45 applications in process.  In December, we noted that the company had three patents with more than fifty in process. View Biophan's patent portfolio here: http://www.biophan.com/intellectual.php I'd like an MRI, please... If I owned a Magnetic Resonance Imaging (MRI) company, I'd buy some shares in Biophan. With the company's stated goal of eventually making all biomedical devices safe for patients who have them and need life-saving MRI's, it simply makes sense. The demographic is aging. More implanted devices--including pacemakers, stents and guidewires--are being used every day. Until Biophan came along, folks who had devices implanted couldn't access MRI's as the metal of their devices, attendant wires etc., put the life-saving imaging procedure out of the reach of many patients.  With Biophan's nanotech based technology, coatings and procedures, an MRI's electromagnetic interference with implanted devices becomes a non-issue, ultimately increasing access to a huge and growing number of patients now and, of course, in the future. Held patents by Biophan and those pending cover an array of products and therapies, including nano-magnetic coatings, radio frequency filters, polymer composites and photonics. There is little doubt that these products and those for which Biophan has patents pending or in development will result in significant improvements in patient care as well as returning substantial value for those shareholders who participate in the company's early growth phase.  That would be now. Taking the Nano view... One other exciting initiative is Biophan's NanoView technology for which it holds an exclusive license. Since 1988, the MRI contrast agent of choice used to detect tissue abnormalities is a ferromagnetic metallic water-soluble substance called Gadolinium.  The benefits of Biophan's NanoView technology over the use of Gadolinium as an MRI contrast agent are many, including non-toxicity, chemical stability and high signal strength. These factors allow for enhanced imaging sensitivity and specificity than can potentially determine the difference between a Breast cancer tumor and a benign cyst.  From a Biophan press release: "NanoView is intended to utilize nanomagnetic particles as contrast agents that preferentially bind to tissues of diagnostic interest, creating improved detail and contrast in images. If successful, this technology would improve signal intensity and permit the use of multiple markers." Exciting, life-saving stuff and yet another reason that investors need to keep a close eye on the progress and potential of Biophan. Given the number of cutting edge initiatives the company is developing, investors who wait for announcements will be disappointed as they watch significant purchase opportunities vaporize. The progress of the development and growth of Biophan's patent portfolio in a very few months is clear evidence that the company is successfully executing its business plan. The stock action during that period further suggests that investors are more than prepared to support the shares at these levels.  We believe that the shares of Biophan should do well from here as more announcements come over the next few weeks and months. I would suggest not being left behind.   PRESS RELEASE Biophan Technologies Substantially Expands Patent Portfolio Total Portfolio Increases to 9 Issued and 6 Allowed Patents in Addition to 45 Applications in Process Rochester, NY, April 27, 2004 -- Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next generation biomedical technology, announced today the allowance of five and issuance of five additional patents, substantially expanding its proprietary technology base, bringing its total portfolio to nine issued and six allowed patents, in addition to forty-five applications in process Biophan has received Notice of Allowance for three patents, each entitled, "An Electromagnetic Interference Immune Tissue Invasive System," and having focus in three distinct areas of photonic and shielding technology and their application to MRI safety for implantable devices such as pacemakers.  The application numbers of these patents are 2002/0133211 A1, 2002/0133200 A1, and 2002/0133199 A1. The company also received Notice of Issuance for three patents that were the subject of a previous press release when they were allowed by the Patent Office.  Two of them share the same title as the above three allowed patents, "An Electromagnetic Interference Immune Tissue Invasive System," and have patent numbers 6,718,203 and 6,718,207; both issuing on April 6, 2004.  The third, "MRI Compatible Medical Device with Passive Generation of Optical Sensing Signals," patent number 6,711,440, issued on March 23, 2004. "Biophan's mission of creating a world-class biomedical patent portfolio is clearly being realized "stated Michael Weiner, CEO of Biophan. "We are pleased to add these patents to our proprietary technology base, bringing our total portfolio to nine issued and six allowed patents, in addition to a notable forty-five applications in process."  Biophan continues to work with its licensor, Nanoset LLC, to broaden their patent portfolio that is under exclusive worldwide license to Biophan for medical applications.  Nanoset recently received Notice of Allowance for two additional applications dealing with optical and shielding applications of its nanomagnetic materials. In addition, Nanoset has received Notice of Issuance for two patents that are also exclusively licensed to Biophan.  They are "Magnetically Shielded Conductor," patent number 6,506,972, issuing on January 14, 2004, and "Magnetically Shielded Assembly," patent number 6,713,671, issuing on March 30, 2004. View Biophan's patent portfolio at http://www.biophan.com/intellectual.php. About Biophan Technologies Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment.  The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI.  The technology is also being used to create enhanced MRI contrast agents.  Committed to growth through innovation and developmental leadership, Biophan and its licensors have nine issued U.S. patents and over fifty patents pending, in areas including nanomagnetic particle coatings, radio frequency filters, polymer composites, and photonics.  Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI.  For more information, please visit www.biophan.com.  About Nanoset, LLC Nanoset, LLC, based in East Rochester, NY, develops nanomagnetic particle coatings.  Nanoset's research and development has been conducted with Alfred University, a world leader in ceramics and thin-film coatings.  Nanoset and Biophan are jointly developing technologies for the medical device industry.  Cautionary Statement Regarding Forward-Looking Statements  Certain statements included in this press release may constitute forward-looking statements.  Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC").  As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC.  The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Contact: Carolyn Hotchkiss Biophan Technologies, Inc. 585.214.2407  Press Interviews:  Michael Weiner  585.214.2441   We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Unsubscribe Here D I S C L A I M E R : The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Click Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has been paid a fee of $25,000 directly by Biophan Technologies, Inc. for reporting on the Company. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with  which the editor is affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.